Porownywarka

Cagrilintide vs CagriSema side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

CagrilintideCagriSema

Udostępnij porównanie peptydów

Wlasciwosc	Cagrilintide	CagriSema
Kategoria	Redukcja masy	Redukcja masy
Znany tez jako	AM833, NN9838, CagriSema (combination)	Semaglutide + Cagrilintide
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Investigational phase 3 program, mainly through CagriSema; source reports an NDA submitted in Dec 2025 with FDA decision expected in Q4 2026. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	NDA submitted Dec 18, 2025; FDA decision expected Q4 2026. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Weight loss, appetite control, combination therapy	Maximum weight loss, combination therapy, obesity
Jak dziala	Cagrilintide is described as a long-acting amylin analog with activity across the amylin and calcitonin receptor family. The source reports signaling through amylin receptor complexes, including receptors formed by calcitonin receptors with RAMP proteins. Reported downstream effects include central satiety signaling, delayed gastric emptying, and moderation of meal-related glucagon increases. Mechanistic animal data in the source emphasize AMY1R and AMY3R pathways involving hindbrain regions such as the area postrema, nucleus of the solitary tract, and parabrachial nucleus. The molecule is described as a modified pramlintide-like 37-amino-acid analog with a fatty-diacid modification intended to extend exposure to about one week.	CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog. The source links semaglutide to insulin response after meals, delayed gastric emptying and fullness signaling, while cagrilintide is described as acting through amylin-related satiety pathways in the brain. The proposed research rationale is that concurrent GLP-1 and amylin signaling may produce stronger appetite effects than either pathway alone.
Typowe dawkowanie	2.4 mg weekly · Once weekly	Limited community data available · See research protocols
Dawkowanie z badań	2.4 mg weekly · Once weekly · Long-term / chronic use expected · Subcutaneous injection once weekly	Semaglutide 2.4 mg + cagrilintide 2.4 mg weekly · Weekly · Long-term use expected · Subcutaneous injection weekly
Typowy czas trwania	Long-term / chronic use expected	Long-term use expected
Podanie	Subcutaneous injection once weekly	Subcutaneous injection weekly
Timing	Any consistent time weekly With or without food	-
Poziom dowodów	Badania kliniczne	Badania kliniczne
Mozliwe skutki uboczne	Nausea (Reported as common and usually temporary in the source.) Vomiting (Listed among reported gastrointestinal effects.) Diarrhea (Listed among reported gastrointestinal effects.) +8 więcej Constipation (Listed among reported gastrointestinal effects.) Abdominal pain (Reported in the source as a gastrointestinal adverse effect.) Injection site reactions (Reported in the source without additional severity detail.) Decreased appetite (Reported in the source; clinical relevance depends on study context.) Headache (Reported in the source without additional severity detail.) Dyspepsia (Reported in the source as a gastrointestinal symptom.) Gastrointestinal events in CagriSema trials (Source reports 79.6% affected, mostly mild to moderate.) Limited long-term safety data (Source notes ongoing trials and incomplete long-term safety characterization.)	Nausea (Reported as a gastrointestinal adverse effect in the source.) Vomiting (Reported as a gastrointestinal adverse effect in the source.) Diarrhea (Reported as a gastrointestinal adverse effect in the source.) +4 więcej Constipation (Reported as a gastrointestinal adverse effect in the source.) Gastrointestinal events (The source reports 72-80% with CagriSema compared with 34-40% for placebo.) Higher gastrointestinal effects than semaglutide alone (Listed in the source side-effect field.) Investigational status (The source notes that CagriSema is not yet approved.)
Podsumowanie researchu	The supplied source describes cagrilintide as having controlled human evidence, including a 2021 phase 2 dose-finding trial in which once-weekly 4.5 mg cagrilintide was associated with about 10.8% mean body-weight loss over 26 weeks, compared with roughly 3% for placebo and about 9% for liraglutide 3.0 mg. The source also highlights phase 3 REDEFINE development for CagriSema in obesity and type 2 diabetes, with weight-loss results reported in the low-20% range for the combination. Gastrointestinal tolerability issues, especially nausea and vomiting, are described as prominent. As presented by the source, cagrilintide remains investigational rather than an approved standalone therapy.	The supplied research summary describes two phase 3 REDEFINE studies. In REDEFINE 1, about 3,400 adults with overweight or obesity without diabetes were followed for 68 weeks; reported average body-weight change was about 20.4% with CagriSema, compared with 14.9% for semaglutide, 11.5% for cagrilintide and 3.0% for placebo. REDEFINE 2 enrolled adults with type 2 diabetes and is described as meeting endpoints for weight reduction and HbA1c improvement versus placebo. The source also notes that the approximately 20% result was below Novo Nordisk's 25% target, and that gastrointestinal events were the most common adverse effects.
Referencje	Źródło Źródło +3 więcej Źródło Źródło Źródło	New England Journal of Medicine New England Journal of Medicine +2 więcej American Diabetes Association Novo Nordisk
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Cagrilintide

CagriSema

Kategoria

Redukcja masy

Znany tez jako

AM833, NN9838, CagriSema (combination)

Semaglutide + Cagrilintide

Zatwierdzony przez FDA

Nie

Status kliniczny

Investigational phase 3 program, mainly through CagriSema; source reports an NDA submitted in Dec 2025 with FDA decision expected in Q4 2026.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

NDA submitted Dec 18, 2025; FDA decision expected Q4 2026.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Weight loss, appetite control, combination therapy

Maximum weight loss, combination therapy, obesity

Jak dziala

Cagrilintide is described as a long-acting amylin analog with activity across the amylin and calcitonin receptor family. The source reports signaling through amylin receptor complexes, including receptors formed by calcitonin receptors with RAMP proteins. Reported downstream effects include central satiety signaling, delayed gastric emptying, and moderation of meal-related glucagon increases. Mechanistic animal data in the source emphasize AMY1R and AMY3R pathways involving hindbrain regions such as the area postrema, nucleus of the solitary tract, and parabrachial nucleus. The molecule is described as a modified pramlintide-like 37-amino-acid analog with a fatty-diacid modification intended to extend exposure to about one week.

CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog. The source links semaglutide to insulin response after meals, delayed gastric emptying and fullness signaling, while cagrilintide is described as acting through amylin-related satiety pathways in the brain. The proposed research rationale is that concurrent GLP-1 and amylin signaling may produce stronger appetite effects than either pathway alone.

Typowe dawkowanie

2.4 mg weekly · Once weekly

Limited community data available · See research protocols

Dawkowanie z badań

2.4 mg weekly · Once weekly · Long-term / chronic use expected · Subcutaneous injection once weekly

Semaglutide 2.4 mg + cagrilintide 2.4 mg weekly · Weekly · Long-term use expected · Subcutaneous injection weekly

Typowy czas trwania

Long-term / chronic use expected

Long-term use expected

Podanie

Subcutaneous injection once weekly

Subcutaneous injection weekly

Timing

Any consistent time weekly

With or without food

Poziom dowodów

Badania kliniczne

Mozliwe skutki uboczne

Nausea (Reported as common and usually temporary in the source.)
Vomiting (Listed among reported gastrointestinal effects.)
Diarrhea (Listed among reported gastrointestinal effects.)

+8 więcej

Constipation (Listed among reported gastrointestinal effects.)
Abdominal pain (Reported in the source as a gastrointestinal adverse effect.)
Injection site reactions (Reported in the source without additional severity detail.)
Decreased appetite (Reported in the source; clinical relevance depends on study context.)
Headache (Reported in the source without additional severity detail.)
Dyspepsia (Reported in the source as a gastrointestinal symptom.)
Gastrointestinal events in CagriSema trials (Source reports 79.6% affected, mostly mild to moderate.)
Limited long-term safety data (Source notes ongoing trials and incomplete long-term safety characterization.)

Nausea (Reported as a gastrointestinal adverse effect in the source.)
Vomiting (Reported as a gastrointestinal adverse effect in the source.)
Diarrhea (Reported as a gastrointestinal adverse effect in the source.)

+4 więcej

Constipation (Reported as a gastrointestinal adverse effect in the source.)
Gastrointestinal events (The source reports 72-80% with CagriSema compared with 34-40% for placebo.)
Higher gastrointestinal effects than semaglutide alone (Listed in the source side-effect field.)
Investigational status (The source notes that CagriSema is not yet approved.)

Podsumowanie researchu

The supplied source describes cagrilintide as having controlled human evidence, including a 2021 phase 2 dose-finding trial in which once-weekly 4.5 mg cagrilintide was associated with about 10.8% mean body-weight loss over 26 weeks, compared with roughly 3% for placebo and about 9% for liraglutide 3.0 mg. The source also highlights phase 3 REDEFINE development for CagriSema in obesity and type 2 diabetes, with weight-loss results reported in the low-20% range for the combination. Gastrointestinal tolerability issues, especially nausea and vomiting, are described as prominent. As presented by the source, cagrilintide remains investigational rather than an approved standalone therapy.

The supplied research summary describes two phase 3 REDEFINE studies. In REDEFINE 1, about 3,400 adults with overweight or obesity without diabetes were followed for 68 weeks; reported average body-weight change was about 20.4% with CagriSema, compared with 14.9% for semaglutide, 11.5% for cagrilintide and 3.0% for placebo. REDEFINE 2 enrolled adults with type 2 diabetes and is described as meeting endpoints for weight reduction and HbA1c improvement versus placebo. The source also notes that the approximately 20% result was below Novo Nordisk's 25% target, and that gastrointestinal events were the most common adverse effects.

Referencje

Źródło Źródło

+3 więcej

Źródło Źródło Źródło

New England Journal of Medicine New England Journal of Medicine

+2 więcej

American Diabetes Association Novo Nordisk

Pełny profil

Zobacz szczegóły